×
About 4,360 results

ALLMedicine™ Acromegaly Center

Research & Reviews  1,423 results

Impact of the COVID-19 pandemic in the treatment of patients with acromegaly in a terti...
https://doi.org/10.20945/2359-3997000000491
Archives of Endocrinology and Metabolism; de Jesus Nunes R, Masullo LF et. al.

Jun 28th, 2022 - The COVID-19 pandemic has profoundly disrupted health care worldwide. We aimed to evaluate the impact of the first COVID-19 wave on the treatment of our patients with acromegaly. A standard questionnaire was systematically applied to all patients ...

Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer.
https://doi.org/10.1038/s41574-022-00702-6 10.1530/EJE-21-0534 10.1038/nrendo.2018.22 10.1056/NEJM193605142142001 10.1126/scitranslmed.3001845 10.1210/er.2018-00216 10.1016/j.cmet.2016.05.014 10.1038/nri1412 10.1016/j.ghir.2017.12.010 10.1152/ajpgi.00413.2004 10.1161/STROKEAHA.117.020557 10.1016/j.matbio.2013.09.005 10.1113/jphysiol.2009.179325 10.1210/er.2018-00115 10.1210/jc.2016-3693 10.1210/clinem/dgz033 10.1016/j.ghir.2011.03.006 10.1210/er.2018-00265 10.1126/scitranslmed.aan4669 10.1530/EJE-10-0208 10.1161/01.CIR.0000129763.51060.77 10.1007/s12020-017-1283-8 10.1016/j.mce.2003.12.004 10.1210/me.2015-1302 10.1038/s41586-020-2403-9 10.1016/j.exger.2020.110836 10.1038/nature16932 10.18632/aging.100681 10.1371/journal.pone.0140189 10.1111/acel.12219 10.1210/jendso/bvab177 10.1161/01.RES.0000257912.78915.af 10.1038/s41419-019-1670-6 10.1038/s41586-020-2938-9 10.1210/endo.138.1.4853 10.1210/endo-125-5-2360 10.1074/jbc.M311467200 10.1074/jbc.M115.701433 10.2741/2918 10.1016/j.clindermatol.2006.04.011 10.1016/0002-8703(80)90277-X 10.1210/jc.2015-2675 10.1002/edm2.90 10.1016/j.jus.2010.09.008 10.4158/EP-2019-0254 10.1210/en.2013-1899 10.1530/JOE-13-0497 10.1007/s11102-021-01179-8 10.1210/en.2018-00850 10.1210/en.2019-00167 10.1016/j.ghir.2015.09.004 10.1038/ctg.2016.72 10.1210/clinem/dgz172 10.1530/EJE-12-0252 10.1053/j.gastro.2005.05.019 10.1111/j.1067-1927.2004.012407.x 10.1111/ced.12407 10.1111/j.0954-6820.1988.tb15881.x 10.1530/EJE-16-0117 10.1016/j.hfc.2019.03.001 10.1111/j.1365-2265.1994.tb01827.x 10.1210/jc.2003-030144 10.1210/er.2013-1071 10.3109/00365519509075396 10.1111/j.0954-6820.1988.tb15882.x 10.1172/JCI102977 10.1530/EJE-19-0509 10.1530/eje.0.1480193 10.1210/jc.2006-2547 10.4158/GL-2019-0405 10.1530/EJE-17-0340 10.1210/jc.2013-1610 10.1016/S0140-6736(00)04006-X 10.1007/s11102-020-01048-w 10.1016/0140-6736(90)91812-O 10.1161/01.HYP.23.6.884 10.1007/s11102-022-01207-1 10.1111/joim.13382 10.1210/er.2008-0027 10.1097/00005792-196311000-00002 10.1016/S0140-6736(87)92270-7 10.1016/0026-0495(95)90004-7 10.1038/nrendo.2013.64 10.1172/JCI119095 10.1046/j.1365-2265.1996.728550.x 10.1210/jc.2003-030840 10.1097/00004872-200310000-00018 10.1530/eje.0.1420254 10.1007/s11154-020-09591-4 10.1210/jcem.87.4.8394 10.1210/jc.2011-0078 10.1172/JCI117544 10.1046/j.1365-2265.2000.00931.x 10.1210/jc.2008-1239 10.1016/S0140-6736(89)92328-3 10.1056/NEJMra043430 10.1073/pnas.89.15.6983 10.1152/ajpendo.00129.2018 10.1210/endo.131.6.1446613 10.1016/S0022-2275(20)32034-4 10.1111/j.1365-2265.1993.tb00974.x 10.1152/jappl.1991.70.2.695 10.1136/bmj.306.6894.1726-a 10.1056/NEJM200003233421202 10.1046/j.1365-2265.2003.01832.x 10.7326/0003-4819-133-2-200007180-00010 10.1210/jc.2004-1657 10.1210/jc.2014-3787 10.1002/bdrc.10003 10.1016/S0008-6363(98)00228-4 10.1210/en.2008-0608 10.1210/endo.137.5.8612517 10.1016/j.metabol.2008.07.024 10.1007/s00467-004-1495-z 10.1210/jc.2005-0091 10.1016/j.ghir.2020.101334 10.3389/fendo.2019.00437 10.1002/cbin.10747 10.1073/pnas.88.2.617 10.1126/science.276.5319.1706 10.1677/joe.0.1320293 10.1007/s12020-014-0327-6 10.1161/CIRCRESAHA.107.148791 10.1210/en.2015-1686 10.1210/me.2008-0265 10.2337/db11-1494 10.2337/db11-0197 10.1016/j.ajpath.2015.01.027 10.1161/CIRCULATIONAHA.116.021805 10.1016/j.celrep.2016.01.044 10.1016/j.cophys.2020.09.002 10.1016/j.celrep.2021.110068 10.1007/s12020-011-9557-z 10.1073/pnas.0406396101 10.20945/2359-3997000000186 10.1002/cbin.10939 10.1038/s41574-019-0280-9 10.1016/j.bjps.2009.10.027 10.1186/s13045-020-00904-3 10.1038/nrc2536 10.3390/cancers11091352 10.1073/pnas.1310589110 10.1172/JCI138540 10.1172/jci.insight.125762 10.1073/pnas.1600561113 10.1007/s11357-017-9966-x 10.1111/acel.12525 10.1158/0008-5472.CAN-09-4502 10.1016/j.ecl.2011.06.001 10.1016/j.stemcr.2014.05.005 10.1038/s41416-020-01172-1 10.1016/j.bbcan.2020.188356 10.1038/s41467-017-01236-6 10.1158/0008-5472.CAN-18-3064 10.18632/aging.203335 10.1111/acel.13506 10.1093/gerona/glp017 10.1530/ERC-12-0042 10.1007/s12672-017-0292-7 10.3390/cancers12123640 10.1038/s12276-018-0197-8 10.1210/endocr/bqab013 10.3390/ijms18112362 10.3390/ijms18061274 10.18632/oncotarget.21812 10.1210/en.2016-1928 10.1038/emm.2014.61 10.18632/oncotarget.15375 10.1038/s41580-020-0237-9 10.1210/jc.2017-01000 10.1073/pnas.0405881101 10.1038/sj.onc.1210917 10.1074/jbc.M115.653261 10.1186/s12885-016-2898-5 10.1016/j.trsl.2019.02.006 10.1126/science.331.6019.837 10.1530/EJE-10-0859 10.1210/er.2018-00166 10.1038/s41392-019-0036-y 10.1016/j.jbc.2021.100588 10.1002/ijc.31308 10.1517/14712598.4.3.421 10.1530/EJE-18-0018 10.1054/ghir.2000.0171 10.1210/en.2019-00132 10.1016/j.ghir.2017.05.005 10.1006/dbio.2000.9975 10.1210/en.2005-0607 10.1093/carcin/bgl138 10.1093/carcin/23.6.977 10.1093/carcin/22.11.1853 10.1034/j.1600-0676.2001.021002149.x 10.1074/jbc.M600224200 10.1111/j.1478-3231.1999.tb00042.x 10.1074/jbc.M212050200 10.1158/0008-5472.317.65.1 10.18632/oncotarget.8715 10.1074/jbc.M100437200 10.1016/j.canlet.2015.05.031 10.1007/s10549-006-9168-1 10.1006/excr.1999.4492 10.1002/pros.21268 10.1210/en.2016-1939 10.3171/jns.1999.91.1.0093 10.3171/jns.2001.94.3.0487 10.1111/jcmm.16160 10.1016/j.canlet.2016.05.031 10.1016/j.ejca.2005.12.012 10.3892/mmr.2014.2185 10.1210/jc.2011-3340 10.1210/jc.2009-1026 10.1007/s12020-016-1085-4 10.1210/en.2004-0225 10.1159/000076764
Nature Reviews. Endocrinology; Kopchick JJ, Basu R et. al.

Jun 25th, 2022 - Since its discovery nearly a century ago, over 100,000 studies of growth hormone (GH) have investigated its structure, how it interacts with the GH receptor and its multiple actions. These include effects on growth, substrate metabolism, body comp...

Growth Hormone
https://emedicine.medscape.com/article/2089136-overview

Jun 24th, 2022 - Reference Range Random growth hormone (GH) levels in a healthy person range as follows [1] : Men - < 5 ng/mL (mcg/L [SI units]) Women - < 10 ng/mL (mcg/L [SI units]) Newborns - 5-23 ng/mL (mcg/L [SI units]) 1 week - 2-27 ng/mL (mcg/L [SI units]) 1...

Growth Hormone
http://emedicine.medscape.com/article/2089136-overview

Jun 24th, 2022 - Reference Range Random growth hormone (GH) levels in a healthy person range as follows [1] : Men - < 5 ng/mL (mcg/L [SI units]) Women - < 10 ng/mL (mcg/L [SI units]) Newborns - 5-23 ng/mL (mcg/L [SI units]) 1 week - 2-27 ng/mL (mcg/L [SI units]) 1...

see more →

Guidelines  5 results

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) ...
https://doi.org/10.1016/j.numecd.2016.02.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Expert consensus document: A consensus on the medical treatment of acromegaly.
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

American Association of Clinical Endocrinologists medical guidelines for clinical pract...
https://www.ncbi.nlm.nih.gov/pubmed/21846616
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.

Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

AME Position Statement on clinical management of acromegaly.
https://www.ncbi.nlm.nih.gov/pubmed/19923883
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.

Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,

Guidelines for acromegaly management: an update.
https://doi.org/10.1210/jc.2008-2421
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.

Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...

see more →

Drugs  27 results see all →

Clinicaltrials.gov  176 results

Genetic Studies of Insulin and Diabetes
https://clinicaltrials.gov/ct2/show/NCT00001987

Jun 24th, 2022 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
https://clinicaltrials.gov/ct2/show/NCT03882034

Jun 24th, 2022 - Growth hormone excess is a rare and potentially lethal condition associated with hypersecretion of growth hormone (GH), usually by a pituitary tumor or hyperplasia. When it occurs prior to the complete fusion of growth plates, it leads to patholog...

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
https://clinicaltrials.gov/ct2/show/NCT05431803

Jun 24th, 2022 - This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN amo...

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
https://clinicaltrials.gov/ct2/show/NCT04076462

Jun 15th, 2022 - The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
https://clinicaltrials.gov/ct2/show/NCT04125836

Jun 15th, 2022 - The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to contin...

see more →

News  106 results

Practice Guidelines Highlights From the Past Year
https://www.medscape.com/viewarticle/969871

Mar 8th, 2022 - Dr Douglas S. Paauw A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin. Her stool toxin test is positive for Clostridio...

Practice guidelines highlights from past year
https://www.mdedge.com/internalmedicine/article/252401/infectious-diseases/practice-guidelines-highlights-past-year
Douglas S. Paauw, MD

Mar 3rd, 2022 - A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin.

Oral Octreotide Shows Promise as Alternative to Injections for Acromegaly
https://www.medscape.com/viewarticle/966233

Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...

Association of Circulating IGF-I with Common Non-cancerous Conditions
https://www.medscape.com/viewarticle/963018

Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficie...

FDA Eyes Oral Testosterone; Phase II Success for Novel Osteoporosis Tx
https://www.medpagetoday.com/endocrinology/generalendocrinology/91617

Mar 14th, 2021 - The FDA accepted a new drug application and set a review date of October 31 for Marius Pharmaceuticals' Kyzatrex, an oral testosterone undecanoate softgel, for primary and secondary male hypogonadism. The Endocrine Society released a new scientifi...

see more →

Patient Education  7 results see all →